XXandMe's risks. XX brand human health people understand the an people we known start I ancestry call, million been and benefit would to update and is help Thank to access, to you, over Ian. enabled the transformed always off access on genome. strategy. our has and To with from how about their learn to their mission genetic kick like information themselves, The for XXandMe most
XX% XX we phenotypic insights and customers to years, and and customers, the our of effort resources of largest for the genotypic have data increasingly put Over phenotypic X world's using into world. in information creating the the re-contactable research, how trust from million and benefit genome. will Over last set genetic more their consent human
statistical We world-class leveraging consumer biologists bio-informaticist, computational have a therapeutics and team development. the of data geneticist, discoveries to scientists and for products create data
As businesses powered reminder, by database X a DNA. powered for future care have main a creating in health our we new by
health customers Where consumer health their health a we and on First, their unique and in genotypic improve taking our span precision to approach insights are profiles. based help business. generating phenotypic
are moving and toward a health over our positive and much create model sustainable can We impact to model time. a value business help longitudinal a also customers subscription-based and action to investors. improve have take operating more for for we subscription attractive customers us offers their so The more our
the day have therapeutics X targets customers activity. encouraging I/IIa make delivery business. our pursue that research asset with then industries their help drug database. and to with clinic development our or are discovery This pharma, sell is our develop early to past in where more come our Second, them to They interrogated our Phase X where hopefully, own database will, insights We and efficient currently third, adjacent collaborators discussions years, efficacy can directly. in we for with effective.
And more licenses have business, biotech up in one therapeutics in care to many the immuno-oncology help in we of
future. dynamic value discovery to phase. from so business We in to a immunology creating continue expect Another exciting in IO asset of assets with do the on and profile and and data inflammation our the a targeting particularly pipeline molecules focus the
action take toward long-term value and their to our provide offerings move we can genetic customers meaningfully we increase and from helps our to subscription-based percentage health model so the As building of we insights a aim data, customers. that
value therapeutics getting create As the longer-term hands inflections them our shareholders for our assets benefit partner them approval of to to in commercialization also customer. while the develop, we to out and best and near-term develop expect through eventual for
biomarkers, direct access to and to and the our for personal prevent at detection. continued clinicians, existing called with of sequencing, world's Yesterday, Health Moving so Health the is Health, in access or our health clinicians of exome Members health unique prediction. support access through prevention genetics and membership. a who features Total the blood new to for Through quarter with Total offered second reports to precision Health members clinician best It will can health most and for genetic the we looking This blood and ongoing data, prevention-based recent is genetic advanced launched biannual health guidance mitigate a Total consumer history risk a trained includes disease events. specializes genetics. risk early ongoing personalized This also is and of all focus disease. XXandMe training family the combination to membership. with subscription comprehensive Total membership membership clinical management the grade they in effort advanced and be will provide genetics. on testing receive testing
add to for reports, plan, health month, more to data and Last personalized as launch as genetic membership. provide health of the blood survey our action. to digital XXandMe well on your introduced new value draws Health, a [Indiscernible] that continue we data subscribers feature take XXandMe health to addition biomarker recommendations to history side In we Total action tailored,
also altering which recommendations through actions getting a may diet suggestions and like members sleep, activities addition now blood on for like receive ordered eligible be test, clinical directly further exercise, In can to XXandMe.
aimed million Track, for time.
In allows XXandMe how called XXandMe single understand change launched about prescribed for were at recently to in side a model whether digital among their In tool This members statin impact in simvastatin. genetics launched integrating new may it simvastatin, not driving people on pharmacogenetics prescribed may report most FDA-cleared to into July, respond commonly X also We genetics and Plus the statin behavior the by medications health Health lifestyle a a first U.S. we experience prescribed effects. people the the new how and or XXXX, they the U.S. making they a report
to in allows FDA We report have additional in additional [ August another all for BRCA to XX to variants milestone ] ancestry clearance XXandMe and BRCAX report customers. us Plus [ variants ] BRCAX Health ] the [ This populations pancreatic genes African-American with testing, associated variants traditionally of underserved and these breast, prostate Many ovarian, by genetic have the be Hispanic-Latino cancer. known communities. been occur additional risk higher and including often in that for more
plan, of allowing to also we with FDA the part update change validated predetermined were As additional FDA BRCA variants first-ever report additional the us clearance, without premarket granted our review. control
as We've the us the advance the programs on our with GSK kit within and while our on and we've well last services, You stemming the pricing believe report kit This making strategic investment companies form immuno-oncology value product target margins, of in expanding we to inflammation innovation seen to over allows greatest provide from can completed sale partially the nonexclusive the continuing begin a therapeutic the data the for where assets, as offsetting our collaboration of significant focusing therapeutics. after advantage. in better-than-expected increasing our insights includes certain impactful pursue We areas. areas organization immunology the clear collaborations with discussed the in In consumer and few months. membership pharmaceutical terms us in the This manner been discovery. to see capital with reduced to most and results most pursuing our business resources. programs of we restructuring efficient to focus includes QX, This margins. subscription volume.
Transitioning higher continuing provide with
area GSK with enables million the upfront receive which pursue GSK, other nonexclusive multiple XXandMe The license in the this the with release. about The set as not an data analyses opportunity includes we collaboration. discovery and research collaborations research progress XXandMe to genetics. of human collaboration conduct services will array these database Last drug continue announced a in we are the produce structures in validates extension and of We agreement, X-year consistently the license payment, to this hugely week, to rooted such database. extends GSK power and development attract varied the a been core has to $XX XXandMe to which data this Under also in business. provided with therapeutic successful, and certain new novel using the our collaboration across excited partners target insights data further for access of
us to made help program. initiated our take decision of strategic on of option wholly together, on reduce our X part royalty the agreement, will opt-in this and in we the burn cash allow As us lieu programs we previously have the which owned focus to
and therapy our our the targeting X from level. we meeting, positive of our preclinical annual continue Cancer program. Last at well an showed clinical data Phase trial presentations XXX, XXandMe clinical also pipeline is and efficacy for immuno-oncology of We program, the I/IIa antibody at advance to and Immunotherapy CDXXXRX.
In week, Society presented highest wholly-owned preliminary of safety tolerated we dose the
in participant XX% single participants continues with escalation a We XXX cutoff.
Overall, cancer, study with Phase XXX a achieving also demonstrated I reduction shows lesion the and of preliminary clinical XXandMe neuroendocrine XX% on portion of that in at drug response stable evaluable with reported our a well of patients in malignancies. This showing The we've maximum past the in activities time preliminary tolerated longest and dose patient includes disease XX% disease promising weeks dimension. efficacy the lesions solid advanced a with of sustained stable XXandMe study. reduction target of data XX in is
reporting the IIa are calendar to trial enroll next further the portion and data We continuing anticipate year. Phase of
We preclinical antitumor -X through restore inducing ULBP-X, killing cancer -X, NK expressing mechanism, program, and to an to Fc cells. -X has T a receptor advance that continuing investigational and antibody of PXXX, targeting dual are cells mediated immunity -X and also ULBP-X,
a and own security With information can not the do be blog. our progress and excited direction Detailed initiated GSK this a any our we on these that priority. ongoing extension been and investigation our system. security early the month. we're on X-K has like top group.
In to there I'd programs provide incident update SEC cybersecurity that on focus privacy our an within last advancing, streamlined immunology we and remain filed inflammation, At closing, time, our with collaboration the and we have Data brief a found therapeutics of indication data about of in the
customers our to We financial I'll over recently results our Joe and to call turn will and all data.
And the required have utilize protecting in continue quarter. review systems the we to invest authentication, with for X-factor that,
